Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Heres What You Should Know
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the companys earnings…
138,070$
2,70%
Echtzeit-Aktienkurs Protagonist Therapeutics
Bid:
Ask:
Nachrichten zur Protagonist Therapeutics Aktie
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight
The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib…
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript
…
Protagonist Therapeutics: MIMRYLO löst mit zweiter FDA-Zulassung 275 Mio. USD an Zahlungen aus
MIMRYLO ist als erstes und einziges Hepcidin-Mimetikum für Erwachsene mit Polycythaemia vera zugelassen. Die FDA-Zulassung löst 275 Mio. USD…
Protagonist Therapeutics: Peptid-Therapien sorgen mit ICOTYDE-Zulassung für Rekordumsatz
Protagonist Therapeutics setzt bei peptidbasierten Therapeutika auf Umsatzbeteiligungen durch strategische Partnerschaften mit führenden Pharmakonzernen. Die FDA-Zulassung von ICOTYDE im…
Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?
Protagonist Therapeutics (PTGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest…
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes
The chief medical officer at one of the top pharmaceutical companies sold nearly 10,000 shares in late January 2026, but…
Protagonist (PTGX) Earnings Call Transcript
Image source: The Motley Fool.DATEWednesday, March 10, 2021 at 10:12 p.m. ETCALL PARTICIPANTSChief Executive Officer — Dinesh PatelChief Medical Officer…
Protagonist Therapeutics - Biotechkonzern im Fadenkreuz von Johnson & Johnson!
Geschäftstreiber: Protagonist Therapeutics (PTGS) hat sich auf die Entwicklung peptidbasierter Therapeutika spezialisiert, wobei man sich auf neue Ansätze zur Behandlung…
Key deals this week: Protagonist Therapeutics, Bristol Myers, Novo Nordisk, Fifth Third Bancorp and more
…
Stocks making the biggest moves midday: MP Materials, Alibaba, Protagonist Therapeutics & more
These are the stocks posting the largest moves midday.…
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports By Reuters
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports…
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports
Johnson & Johnson is in discussions to buy Protagonist Therapeutics , the Wall Street Journal reported on Friday, citing people…
Protagonist Therapeutics stock surges after J&J acquisition talks report
Protagonist Therapeutics stock surges after J&J acquisition talks report…
Protagonist (PTGX) Q2 Revenue Falls 26%
Key PointsGAAP loss per share of $0.55 in Q2 2025 beat analyst estimates by $1.13.GAAP revenue of $5.5 million in…
Protagonist Therapeutics: Two Slam Dunk Sets Of Pivotal Data Set Up Bull Case
…
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 62% and 149.90%, respectively, for the quarter ended March 2025. Do…
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
The consensus price target hints at a 27.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this…
Protagonist Therapeutics (PTGX) Upgraded to Buy: Heres Why
Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to…
Protagonist Therapeutics: Transformation des Gesundheitswesens mit erstklassigen Peptidmedikamenten
Protagonist Therapeutics ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entdeckung und Entwicklung von peptidbasierten Therapeutika konzentriert.…
Truist raises Protagonist Therapeutics target to $76 By Investing.com
Truist raises Protagonist Therapeutics target to $76…
4 Stocks to Buy for Attractive Earnings Acceleration
Invest in stocks such as Protagonist Therapeutics (PTGX), Evolus (EOLS), Western Digital (WDC), and Phunware (PHUN) as of now for…
4 Must-Buy Stocks for Remarkable Earnings Acceleration
Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics (PTGX), AxoGen (AXGN),…